Premium
Pentoxyfylline in and prevention and treatment of chronic lung disease
Author(s) -
Lauterbach R,
Pawlik D,
Zembala M,
SzymuraOleksiak J,
LisowskaMiszczyk I,
Kowalczyk D,
Bury J
Publication year - 2004
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2004.tb03043.x
Subject(s) - medicine , dexamethasone , asthma , sepsis , bronchodilator , diuretic , respiratory disease , intensive care medicine , clinical trial , disease , lung
The anti‐inflammatory effects of pentoxfylline are associated with a number of clinical benefits. These include reduction in mortality in patients who have undergone bone marrow transplants or suffer peritonitis. In infants with sepsis, a reduction in mortality has also been associated with pentoxyfylline administration. The anti‐inflammatory effects of pentoxyfylline, as well as its bronchodilator, diuretic and respiratory muscle stimulant effects suggest it may have a useful role in BPD. Interim analysis of a prophylactic trial suggests pentoxyfylline may reduce treatment requirements after the neonatal period and that, in established BPD, pentoxyfylline and dexamethasone may be of similar efficacy.